Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Comparison of the metabolome and lipidome of wild type and mdx/mTR mice (Study ST000753)

C18 NEGATIVE ION MODE (Analysis AN001181)

Metabolite	Structure	F1	F2
PG 42:9; [M-H]-@4.79	ME208727	1.61	0.39
PG 38:7; [M-H]-@4.33	ME208721	1.59	0.41
PG 40:7; [M-H]-@5.02	ME208724	1.58	0.42
PG 40:8; [M-H]-@4.67	ME208725	1.66	0.34
PG 42:10; [M-H]-@4.56	ME208726	1.71	0.29
PG 44:11; [M-H]-@4.77	ME208728	1.70	0.30
PG 44:12; [M-H]-@4.48	ME208729	1.70	0.30
PE 30:1; [M-H]-@5.57	ME208666	1.25	0.75
PS 40:5; [M-H]-@6.04	ME208740	1.24	0.76
PI 40:5; [M-H]-@5.98	ME208735	1.24	0.76
PE 38:1; [M-H]-@7.95	ME208683	1.24	0.76
FFA(24:1)	ME208618	1.24	0.76
PC 33:2; [M-Ac-H]-@6.04	ME208638	1.24	0.76
plasmenyl-PE 36:5; [M-H]-@6.29	ME208755	1.27	0.73
PG 40:5; [M-H]-@6.03	ME208722	1.26	0.74
CL 74:7; [M-2H](2-)@9.36	ME208597	1.26	0.74
PC 36:1; [M-Ac-H]-@7.40	ME208645	1.26	0.74
PG 36:4; [M-H]-@4.89	ME208715	1.14	0.86
CL 72:7; [M-2H](2-)@9.12	ME208591	1.14	0.86
PG 35:1; [M-H]-@6.15	ME208711	1.14	0.86
PS 42:10; [M-H]-@4.81	ME208745	1.15	0.85
PI 40:6; [M-H]-@5.78	ME208736	1.15	0.85
PG 34:1; [M-H]-@5.78	ME208708	1.15	0.85
PE 37:5; [M-H]-@6.21	ME208681	1.15	0.85
PE 44:10; [M-H]-@6.36	ME208701	1.15	0.85
PC 35:2; [M-Ac-H]-@6.64	ME208642	1.17	0.83
PG 34:2; [M-H]-@5.36	ME208709	1.16	0.84
PG 38:3; [M-H]-@5.90	ME208717	1.16	0.84
plasmenyl-PE 38:3; [M-H]-@7.56	ME208758	1.18	0.82
PE 37:1; [M-H]-@7.69	ME208679	1.18	0.82
CL 72:6; [M-2H](2-)@9.28	ME208590	1.18	0.82
CL 74:3; [M-2H](2-)@6.36	ME208596	1.18	0.82
plasmenyl-PE 40:4; [M-H]-@7.74	ME208760	1.19	0.81
CL 74:1; [M-2H](2-)@6.78	ME208593	1.19	0.81
PI 38:3; [M-H]-@6.10	ME208732	1.19	0.81
PG 36:2; [M-H]-@5.84	ME208713	1.22	0.78
PS 40:7; [M-H]-@5.34	ME208742	1.20	0.80
CL 66:3; [M-2H](2-)@5.74	ME208585	1.20	0.80
PC 38:1; [M-Ac-H]-@8.07	ME208653	1.20	0.80
plasmenyl-PE 38:4; [M-H]-@7.22	ME208759	1.21	0.79
PG 32:1; [M-H]-@5.25	ME208705	1.21	0.79
PE 35:2; [M-H]-@6.75	ME208673	1.21	0.79
CL 76:9; [M-2H](2-)@9.29	ME208602	1.21	0.79
PC 40:4; [M-Ac-H]-@7.38	ME208660	1.21	0.79
PG 36:3; [M-H]-@5.39	ME208714	1.45	0.55
PE 36:1; [M-H]-@7.46	ME208677	1.47	0.53
PG 36:5; [M-H]-@4.31	ME208716	1.48	0.52
PI 38:5; [M-H]-@5.33	ME208734	1.34	0.66
PS 38:4; [M-H]-@6.05	ME208738	1.33	0.67
FFA(24:3)	ME208620	1.33	0.67
PG 38:4; [M-H]-@6.07	ME208718	1.33	0.67
CL 72:5; [M-2H](2-)@9.47	ME208589	1.36	0.64
PI 36:2; [M-H]-@5.91	ME208730	1.38	0.62
PE 40:4; [M-H]-@7.44	ME208692	1.37	0.63
PS 42:7; [M-H]-@6.02	ME208746	1.37	0.63
PI 36:4; [M-H]-@5.25	ME208731	1.41	0.59
FFA(24:2)	ME208619	1.39	0.61
PG 38:5; [M-H]-@5.52	ME208719	1.40	0.60
FFA(20:2)	ME208612	0.76	1.24
PE 40:10; [M-H]-@5.12	ME208690	0.76	1.24
FFA(18:1)	ME208608	0.74	1.26
PE 44:12; [M-H]-@5.71	ME208702	0.74	1.26
plasmenyl-PE 42:6; [M-H]-@7.76	ME208762	0.75	1.25
PE 33:0; [M-H]-@7.07	ME208668	0.75	1.25
PE 42:11; [M-H]-@5.41	ME208697	0.75	1.25
PE 42:2; [M-H]-@8.48	ME208698	0.72	1.28
PC 33:1; [M-Ac-H]-@6.50	ME208637	0.70	1.30
PC 42:1; [M-Ac-H]-@9.21	ME208663	0.68	1.32
PC 44:12; [M-Ac-H]-@5.66	ME208664	0.59	1.41
CL 74:10; [M-2H](2-)@8.94	ME208594	0.57	1.43
N-(docosanoyl)-sphing-4-enine; [M-H]-@8.45	ME208622	0.58	1.42
FFA(18:2)	ME208609	0.66	1.34
PE 35:4; [M-H]-@6.06	ME208675	0.66	1.34
CL 76:11; [M-2H](2-)@9.01	ME208600	0.64	1.36
PC 39:8; [M-Ac-H]-@5.48	ME208659	0.63	1.37
plasmenyl-PE 38:1; [M-H]-@8.24	ME208756	0.62	1.38
plasmenyl-PE 42:4; [M-H]-@8.12	ME208761	0.92	1.08
PE 39:7; [M-H]-@6.07	ME208687	0.92	1.08
PE 36:0; [M-H]-@7.88	ME208676	0.92	1.08
PC 39:5; [M-Ac-H]-@6.70	ME208656	0.92	1.08
CL 78:12; [M-2H](2-)@9.07	ME208603	0.92	1.08
PC 36:0; [M-Ac-H]-@7.98	ME208644	0.92	1.08
PE 37:6; [M-H]-@5.98	ME208682	0.93	1.07
PC 37:1; [M-Ac-H]-@7.76	ME208648	0.93	1.07
FFA(20:0)	ME208610	0.93	1.07
lysoPE 20:4; [M-H]-@1.32	ME208750	0.93	1.07
PE 36:6; [M-H]-@5.57	ME208678	0.91	1.09
PI 40:7; [M-H]-@5.26	ME208737	0.91	1.09
CL 74:11; [M-2H](2-)@8.76	ME208595	0.89	1.11
plasmenyl-PE 32:0; [M-H]-@7.11	ME208752	0.89	1.11
PS 38:6; [M-H]-@5.22	ME208739	0.90	1.10
PC 31:0; [M-Ac-H]-@6.30	ME208632	0.90	1.10
FFA(18:0)	ME208607	0.90	1.10
PC 30:0; [M-Ac-H]-@6.02	ME208629	0.90	1.10
PG 38:6; [M-H]-@5.34	ME208720	0.85	1.15
PE 42:10; [M-H]-@5.73	ME208696	0.85	1.15
PC 41:6; [M-Ac-H]-@7.20	ME208662	0.85	1.15
PC 30:1; [M-Ac-H]-@5.49	ME208630	0.85	1.15
N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.90	ME208626	0.85	1.15
CL 80:15; [M-2H](2-)@8.93	ME208605	0.85	1.15
N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.46	ME208621	0.85	1.15
N-(eicosanoyl)-sphing-4-enine; [M-H]-@7.97	ME208623	0.84	1.16
plasmenyl-PE 30:0; [M-H]-@6.47	ME208751	0.84	1.16
PC 40:7; [M-Ac-H]-@6.18	ME208661	0.86	1.14
PC 39:7; [M-Ac-H]-@6.03	ME208658	0.88	1.12
PG 33:1; [M-H]-@5.56	ME208707	0.87	1.13
PE 31:1; [M-H]-@5.99	ME208667	0.87	1.13
FFA(16:0)	ME208606	0.87	1.13
N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.38	ME208625	0.87	1.13
PE 39:8; [M-H]-@5.64	ME208688	0.79	1.21
PE 44:7; [M-H]-@7.51	ME208703	0.79	1.21
PE 41:6; [M-H]-@7.09	ME208694	0.83	1.17
PC 32:2; [M-Ac-H]-@5.67	ME208635	0.83	1.17
FFA(20:4) Arachidonic acid	ME208613	0.83	1.17
PC 30:2; [M-Ac-H]-@5.03	ME208631	0.83	1.17
PE 40:6; [M-H]-@6.91	ME208693	0.81	1.19
CL 76:12; [M-2H](2-)@8.84	ME208601	0.81	1.19
FFA(20:1)	ME208611	0.81	1.19
PE 37:2; [M-H]-@7.31	ME208680	0.82	1.18
PC 39:6; [M-Ac-H]-@6.47	ME208657	0.82	1.18
PC 28:0; [M-Ac-H]-@5.33	ME208627	0.82	1.18
PC 37:7; [M-Ac-H]-@5.33	ME208652	0.82	1.18
lysoPE 16:0; [M-H]-@1.68	ME208747	1.07	0.93
PE 30:0; [M-H]-@6.10	ME208665	1.08	0.92
CL 70:5; [M-2H](2-)@9.23	ME208586	1.08	0.92
lysoPE 18:1; [M-H]-@1.83	ME208748	1.08	0.92
PE 34:2; [M-H]-@6.43	ME208670	1.09	0.91
FFA(22:3)	ME208617	1.09	0.91
CL 72:8; [M-2H](2-)@8.92	ME208592	1.09	0.91
FFA(22:1)	ME208615	1.09	0.91
PS 40:8; [M-H]-@4.90	ME208743	1.10	0.90
PI 38:4; [M-H]-@5.87	ME208733	1.10	0.90
PE 34:3; [M-H]-@5.96	ME208671	1.10	0.90
PC 38:3; [M-Ac-H]-@7.23	ME208655	1.10	0.90
N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.83	ME208624	1.10	0.90
PC 36:5; [M-Ac-H]-@5.76	ME208647	1.10	0.90
FFA(22:2)	ME208616	1.12	0.88
PG 32:0; [M-H]-@5.75	ME208704	1.12	0.88
PE 39:5; [M-H]-@6.79	ME208686	1.11	0.89
PC 35:1; [M-Ac-H]-@7.13	ME208641	1.11	0.89
PE 35:3; [M-H]-@6.28	ME208674	1.11	0.89
PC 36:4; [M-Ac-H]-@6.15	ME208646	1.01	0.99
PS 40:6; [M-H]-@5.79	ME208741	1.02	0.98
plasmenyl-PE 38:2; [M-H]-@7.85	ME208757	1.02	0.98
CL 76:10; [M-2H](2-)@9.21	ME208599	1.02	0.98
PE 42:3; [M-H]-@8.12	ME208699	1.02	0.98
PE 40:2; [M-H]-@8.00	ME208691	1.05	0.95
PG 34:3; [M-H]-@4.97	ME208710	1.04	0.96
PE 40:1; [M-H]-@8.47	ME208689	1.04	0.96
PE 34:4; [M-H]-@5.67	ME208672	1.04	0.96
PE 33:2; [M-H]-@6.07	ME208669	1.04	0.96
CL 74:8; [M-2H](2-)@9.17	ME208598	1.04	0.96
PC 32:1; [M-Ac-H]-@6.12	ME208634	1.04	0.96
plasmenyl-PE 36:1; [M-H]-@7.74	ME208754	1.03	0.97
PE 42:1; [M-H]-@8.94	ME208695	1.03	0.97
PC 34:3; [M-Ac-H]-@5.82	ME208639	1.03	0.97
PC 35:3; [M-Ac-H]-@6.18	ME208643	1.03	0.97
PC 37:4; [M-Ac-H]-@6.62	ME208651	0.95	1.05
lysoPE 18:2; [M-H]-@1.34	ME208749	0.95	1.05
PC 34:4; [M-Ac-H]-@5.55	ME208640	0.95	1.05
plasmenyl-PE 32:1; [M-H]-@6.58	ME208753	0.96	1.04
PG 33:0; [M-H]-@6.05	ME208706	0.96	1.04
PE 42:9; [M-H]-@6.07	ME208700	0.96	1.04
CL 70:7; [M-2H](2-)@5.76	ME208587	0.96	1.04
PE 38:3; [M-H]-@7.26	ME208684	0.96	1.04
FFA(22:0)	ME208614	0.97	1.03
CL 72:1; [M-2H](2-)@7.71	ME208588	0.97	1.03
CL 78:13; [M-2H](2-)@8.93	ME208604	0.97	1.03
PS 40:9; [M-H]-@4.43	ME208744	1.00	1.00
PC 31:1; [M-Ac-H]-@5.84	ME208633	1.00	1.00
PC 37:3; [M-Ac-H]-@6.82	ME208650	1.00	1.00
PG 36:0; [M-H]-@6.89	ME208712	0.98	1.02
PC 29:0; [M-Ac-H]-@5.69	ME208628	0.98	1.02
PE 39:4; [M-H]-@7.25	ME208685	0.98	1.02
PG 40:6; [M-H]-@5.98	ME208723	0.99	1.01
PC 38:2; [M-Ac-H]-@7.57	ME208654	0.99	1.01
PC 33:0; [M-Ac-H]-@6.89	ME208636	0.99	1.01
PC 37:2; [M-Ac-H]-@7.29	ME208649	0.99	1.01

Factors:

F1	Genotype:mdx/mTR
F2	Genotype:WT

Data matrix